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Abstract
We performed a review of all direct oral anticoagulant (DOAC) levels – ecarin times for dabigatran 
and anti-Xa levels for rivaroxaban and apixaban – ordered at our institution with the purpose of 
evaluating DOAC levels from “real-world” (non-clinical trial) patients taking DOACs long-term, 
in order to assess levels obtained, reasons for checking levels, and actions taken based on the 
testing result. A total of 28 patients had 48 levels sent over a 36-month period. The majority of 
outpatient levels were within or close to the range of published values. The setting in which levels 
were sent influenced how results affected management decisions: in the outpatient setting, the 
majority of levels served to reassure clinicians that DOAC levels were within expected ranges 
resulting in continuation of chosen management, whereas in the inpatient setting, DOAC levels 
were used most frequently to detect DOAC presence in urgent clinical situations and influenced 
clinical decision-making in the peri-procedural and pre-operative periods. Our results demonstrate 
that while testing may be useful if immediately available in urgent clinical situations where 
assessment of drug presence is needed, DOAC level monitoring is infrequently used overall, and 
the lack of use combined with the paucity of available evidence to guide clinical decision-making 
based on the results suggests there is little urgency to make the tests widely available for routine 
use outside of acute settings in the emergency department and urgent surgical setting.
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 Introduction/ Background
Four direct oral anticoagulants (DOAC) are currently approved in the United States and 
other countries for the treatment of venous thromboembolic disease and for stroke 
prevention in atrial fibrillation: the thrombin inhibitor dabigatran, and the factor Xa 
inhibitors apixaban, rivaroxaban, and edoxaban. DOACs are given at fixed doses and are 
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marketed for use without the need for routine monitoring. However, there are instances in 
which measurement of anticoagulant activity may be desirable, such as prior to surgery to 
detect residual anticoagulant drug effect, in the setting of bleeding complications or 
occurrence of thrombosis while on anticoagulant therapy, in the case of suspected non-
compliance, and in special patient populations such as extremes of body weight and renal 
impairment.
Assays for measuring the effects of anti-Xa drugs (via anti-Xa levels) and dabigatran (ecarin 
clot time, dilute thrombin time [dTT]) have been validated for clinical testing, though they 
are not yet FDA approved or widely available. However, interpretation of the DOAC levels 
is difficult. Most published information of DOAC levels at particular doses comes from 
plasma levels obtained from small studies of healthy volunteers or pharmacokinetic 
modeling from phase II and III studies,[1-10] making the applicability to actual patients 
taking the drugs chronically questionable. Data on levels from non-clinical trial patients is 
limited to a small number of case series with small to moderate numbers of patients.[11-14]
Furthermore, while “expected ranges” or “on- therapy ranges” of drug levels have been 
published, therapeutic ranges of dabigatran levels and anti-Xa anticoagulant levels have not 
been defined. While two studies found an association between drug levels and clinical 
outcomes-namely, that the risk of major bleeding is increased as plasma levels of edoxaban 
and dabigatran increase, and the risk of ischemic stroke and systemic thromboembolism is 
associated with lower drug levels [6,15] - no studies have correlated clinical outcomes with 
specific drug levels. Thus, clinical decisions, such as dose-adjustments based on drug levels, 
are problematic and no evidence exists for the effectiveness of such practice. And, indeed, 
while clinical practice statements recognize that these levels can be used to detect drug 
presence or to quantify drug levels, they give no further guidance on how to interpret results 
or adjust drug dosing based on levels.[16,17]
In this manuscript, we review the DOAC levels ordered at our institution, in order to publish 
actual plasma levels from patients taking the drugs long-term in comparison to published 
expected levels, to review the indications for DOAC level testing, and to review management 
decisions based on the results.
 Methods
This study was approved by the Institutional Review Board of the University of North 
Carolina. Through query of our clinical laboratories, we identified patients who had 
rivaroxaban anti-Xa testing, apixaban anti-Xa testing, or dabigatran ecarin time (ECT) 
ordered at our institution from June 2012 through July 2015 (edoxaban levels were not 
available for clinical testing at our institution during this time). We then performed a 
retrospective chart review to collect data, including demographic information, laboratory 
data, and clinical information such as indication for anticoagulation, medication dosage, and 
reason for sending a drug level. Data was extracted from the medical records by one 
reviewer (KM).
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At our institution, apixaban anti-Xa and rivaroxaban anti-Xa levels are sent out to a 
collaborating laboratory, and while anti-Xa levels are ordered, the test is actually run by 
liquid chromatography- mass spectrometry (LC-MS) and reported as anti-Xa drug level by 
the collaborating laboratory. Dabigatran ecarin times are performed in-house.
 Results
 Patient population
A total of 28 patients had 48 DOAC levels sent at our institution over the specified time 
period (Table 1). Nearly half (57%) of patients were female, and the age of patients ranged 
from 21 to 88 years, with a median age of 47 years. Body mass index (BMI) ranged from 
14.9 kg/m2 to 66.8 kg/m2, with a median BMI of 31.3 kg/m2, and weight ranged from 44.5 
kg to 203.9 kg, with a median of 101.9 kg. Most patients (86%) had an estimated glomerular 
filtration (eGFR) of greater than 60 mL/min/1.73m2, with the exception of one patient with 
an eGFR of 11 mL/min/1.73m2 and three patients with eGFRs ranging from 30-60 mL/min/
1.73m2.
 Drug levels
A total of 48 levels have been sent for testing over the specified time period, June 2012 
through the first half of 2015. While no levels were sent in 2012 and only two levels were 
sent in 2013, the number of levels sent for testing significantly increased to 29 in 2014 with 
the availability of apixaban and rivaroxaban testing. Through the first half of 2015, the 
numbers of levels sent for testing remained approximately the same as in 2014, totaling 17.
Eight patients had a total of nine apixaban levels sent, including one patient who had a peak 
and trough pair. Fifteen patients had 24 rivaroxaban levels sent, including four patients with 
peak and trough pairs, and five patients had 15 dabigatran levels sent. Apixaban anti-Xa 
levels ranged from 93.3 to 274 ng/mL. Six of eight patients taking apixaban were dosed at 5 
mg twice daily, and for those patients, peak apixaban anti-Xa levels ranged from 110.6 to 
240.3 ng/mL, with mean peak level of 184.9 ng/mL. Rivaroxaban anti-Xa levels ranged from 
0 to 459.8 ng/mL. Fourteen of fifteen patients in the rivaroxaban cohort were taking a dose 
of 20 mg daily; for these patients peak values ranged from 123.7 to 459.8 ng/mL, with a 
mean peak of 202.0 ng/mL. There were four trough rivaroxaban anti-Xa levels for subjects 
on 20 mg daily, with values ranging from 0 to 37.8 ng/mL, with a mean trough of 17.6 
ng/mL. As noted above, most dabigatran levels were checked in the pre-operative or pre-
procedural setting with intent of monitoring until low levels were obtained, rather than for 
range estimates. Ten obese patients with a BMI >40 kg/m2 had DOAC levels sent, including 
three on apixaban and seven on rivaroxaban, and two of these patients had a trough level 
measured at 0 ng/mL.
 Testing indications
Sixteen levels from six patients were sent when the patients were inpatient and 32 levels sent 
on 22 outpatients. The majority of dabigatran levels (13 levels in 3 patients) were checked 
pre-operatively or pre-procedurally. Extremes of body weight represented the most common 
reason for checking DOAC levels, with 15 levels checked in nine obese patients, and five 
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levels checked in two patients with low body weight. Other indications for checking anti-Xa 
levels included concern for drug failure (five patients, five levels), post-gastrointestinal 
surgery (two patients, two levels), and concern for medication interaction (one patient, two 
levels).
 Clinical consequences of test results
Of the levels checked in the outpatient setting, the results had several consequences. In 82% 
(9/11) of patients with extreme body weights and one patient post-gastric bypass (Table 1, 
patient 21), levels fell within published ranges, leading to clinician's comfort in continuing 
the chosen management. Levels fell below the expected ranges in two patients with obesity 
and one patient post-bowel resection (Table 1, patient 22), but no action was taken based on 
results for unclear reasons. In one patient on an antifungal medication (Table 1, patient 20), 
the DOAC level did not significantly change after starting the antifungal medication, leading 
to comfort in continuing both medications concurrently. In the 5 patients for whom testing 
was sent because of new thrombotic symptoms, one was determined to have “failed” DOAC 
and was switched to low molecular weight heparin (LMWH) in the setting of malignancy 
(Table 1, patient 7), another was determined not to have an indication for anticoagulation 
and was started on aspirin (Table 1, patient 4), and the remaining three were ultimately 
determined not to have recurrent thrombosis and were maintained on the same dose when 
levels were within expected ranges.
Of levels checked in the inpatient setting to detect drug presence, DOAC results influenced 
management decisions: the presence of dabigatran as determined by ECT delayed surgery 
and procedures for two patients, including central line placement and renal biopsy, as the 
bleeding risk was thought to be too high given the level of dabigatran. For another patient, 
the dabigatran level drawn pre-operatively was undetectable, and she, therefore, underwent 
the scheduled surgery.
 Discussion
Our case series adds to the growing body of data of DOAC levels in actual patients taking 
the drugs long-term, supplementing the available literature of published DOAC levels that 
have been obtained mostly from healthy volunteer studies or from PK/PD modeling of large 
clinical trials.[11-14, 18]
Our data show that the rivaroxaban levels in our patients are generally comparable to 
published levels, though the lowest peak and trough levels in our study were lower than the 
low ends of most published data. This particularly holds true for the obese patients in our 
cohort taking rivaroxaban, for which two out of five trough levels were 0, suggesting 
possible under-dosing of rivaroxaban in these patients. Published apixaban drug level data 
are less plentiful than for rivaroxaban and lack ranges of mean values, though our median 
peak as well as two trough levels of apixaban are higher than the means published for 5 mg 
twice daily dose.[2, 19] As described above, the majority of dabigatran levels at our 
institution were drawn in order to detect presence of drug prior to proceeding with 
procedures and/or operations, but the two values that were checked as outpatients are 
consistent with published ranges.[6, 12] Our data also confirms the wide inter-patient 
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variability that has been described previously in a small number of studies.[12-14, 18] The 
retrospective nature of our study depended on the chart documentation of the times the drugs 
were taken by the patient and, therefore, the peak and trough timing of levels may not be 
precise; however, this is representative of “real-world” management of anticoagulation in 
clinical practice.
We found the reasons that DOAC levels were checked consistent with published proposals 
on why levels might be checked;[17] the most common reason for testing in our cohort was 
extreme of body weight- mostly obesity, but also low body weight. Other indications for 
checking levels included recurrent thrombosis, past bowel resections with concerns for drug 
suboptimal absorption, and medication interactions. In our study, the setting and reasons for 
testing influenced actions taken based upon the result: levels checked in the outpatient 
setting were used to reassure clinicians that DOAC levels were within expected ranges, 
leading to comfort in continuing present management, while in the inpatient setting, clinical 
decisions and management were influenced by DOAC testing with timing of surgery/
procedures affected by dabigatran level results.
While there has been interest in the general medical community in making drug levels more 
widely and readily available, our experience suggests testing is uncommonly used and rarely 
affects routine decision-making, and, therefore, may not be urgently needed. We estimate 
that approximately 500 patients are on DOACs and followed regularly by a provider at our 
institution at any given time, and despite this high-volume, DOAC testing has been 
infrequently used since testing has been available (one year for rivaroxaban and apixaban 
anti-Xa levels and three years for dabigatran ECT). We acknowledge that the volume of 
testing may be influenced by both lack of provider awareness of the existence of such tests 
as well as slow turn-around time (currently samples for apixaban and rivaroxban level 
testing are sent out to collaborating labs and typical results return in approximately ten 
days), although we would not expect the long turn-around time to significantly influence 
decisions to send tests on more routine monitoring in the outpatient setting. In addition to 
infrequent use of DOAC level testing, data is lacking on how to make clinical decisions 
based on these levels: for only two studies have correlations between plasma drug levels and 
clinical outcomes in patients with atrial fibrillation been published, demonstrating that the 
risk for thrombosis increases as plasma levels of dabigatran decrease,[6] and the risk for 
major bleeding increases with higher dabigatran and edoxaban levels.[6, 15] Correlations 
between specific drug levels and clinical outcomes (thrombosis or bleeding), however, have 
not been established. Interpretation of results is also hampered by the fact that for at least 
one DOAC, dabigatran, there is significant intra-individual drug level variation when testing 
the same patient at different times [18]; there have not been studies to date about intra-
patient variability in the anti-Xa inhibitors.
As seen by our data – preoperative dabigatran plasma levels to determine best time for an 
urgent surgery and procedures – and as proposed by other authors, DOAC level testing may 
be useful in urgent and emergent situations in which assessment of drug presence is needed, 
such as trauma, stroke, hemorrhage, or need for emergent surgery or procedures.[20-23] 
These situations represent instances in which assays with drug-specific calibrations would 
be helpful to allow for rapid assessment of DOAC levels. The value of such tests, however, 
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depend on their turn-around time, and as such, would need to be performed in-house. In the 
absence of widespread availability of DOAC–specific calibration, alternatives such as anti-
Xa assays with low-molecular weight heparin calibration may be useful in excluding 
significant anti-Xa drug levels,[20, 24, 25] which may make immediate availability of drug-
specific anti-Xa assays less critical.
In conclusion, our results demonstrate plasma levels attained from actual patients taking the 
drugs long-term to supplement published data from volunteers and clinical trials. We found 
that DOAC drug level testing is uncommonly used in routine clinical practice at our 
institution that sees a high-volume of patients anticoagulated with DOACs. While immediate 
availability of drug level assessment is likely beneficial in situations where urgent 
assessment of drug presence is needed, such as trauma, stroke, hemorrhage, or need for 
emergent surgery or procedures, our data suggest that there is otherwise little urgency to 
make the DOAC testing widely available for routine clinical practice. Moreover, 
interpretation and clinical management using DOAC-level results becomes challenging in 
light of the absence of data to guide management in dosing based on these levels. Further 
work is needed to establish correlation between specific drug levels and clinical outcomes in 
order to determine appropriate indications for testing and to maximize the utility of DOAC 
testing.
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Highlights
• DOAC testing results from patients taking anticoagulation long-term are 
presented
• Reasons for testing and clinical consequences of DOAC level results are 
explored
• DOAC level testing is infrequently used at our institution
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